Abstract Library

#4585 Short-term observation of liver transplantation combined with multidisciplinary integrated treatment of liver metastases from neuroendocrine tumours beyond the Milan criteria

Introduction: The continuous progress of comprehensive treatment enables neuroendocrine tumour liver metastasis (NENLM) that meets Milan criteria to achieve longer survival without liver transplantation (LT). LT often faces high tumour burden, while comprehensive treatment also brings new opportunities for recurrence.

Conference:

Presenting Author: Chen C

Authors: Chen C, Jiang W, Chen J, Liang Y, Xie Y,

Keywords: liver transplantation, neuroendocrine tumour liver metastasis, Milan Criteria, comprehensive treatment,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4524 SIRT7 drives the radioresistance of pancreatic neuroendocrine tumours via the DNMT1-MEN1 axis

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are a rare and highly heterogeneous type of tumour in the pancreas. After failure of standard treatment, patients have poor prognoses. Radiotherapy may be a potential therapeutic modality for such patients. However, PanNETs usually exhibit a radiation “cold” tumour through unclarified mechanisms.

Conference:

Presenting Author: Jianyun J

Authors: Jiang J, Xu J, Liang Y, Chen L, Ji S,

Keywords: pancreatic neuroendocrine tumour, radio resistance, SIRT7, MEN1,

#4514 Liver debulking surgery is benefit to PFS in patients with high tumour burden of neuroendocrine tumour liver metastases

Introduction: Liver debulking surgery has shown its definite effect on prolonging survival in patients with neuroendocrine tumour liver metastases (NETLM). However, the effect of liver debulking surgery on the high burden of NETLM is still not clear.

Conference:

Presenting Author:

Authors: Zhou J, Liang Y, Chen J, Wang L,

Keywords: liver debulking surgery, NETLM,

#4501 Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,